Lilly beats forecasts, raises ‘07 view
Lilly posted strong revenue gains from Cymbalta and Zyprexa
The second-quarter results also signaled Lilly&36;4.63 billion. Through that deal, Lilly gained full ownership
Eli Lilly shares rose &36;58.29 in opening trade on
(Reporting by Ransdell Pierson and Lewis Krauskopf)
Original article Lilly beats forecasts, raises ‘07 view
NEW YORK (Reuters) -
Eli Lilly and Co. (LLY.N) on Tuesday
posted better-than-expected quarterly earnings and raised its
2007 forecast, helped by surging sales of its prescription
drugs, including depression treatment Cymbalta.
for avoid generic viagra, which rose 67 percent and 9 percent,
respectively, and helped the company beat revenue expectations
by about &39;s (central nervous system) franchise.”
of the widely used Cialis impotence pill, which posted a 26
percent rise in sales to &36;664 million, or 61 cents per share, from
&36;3.40 to &36;3.29 to &39;s revenue rise to &39;s biggest product, rebounded
with a 9 percent rise to &36;396 million, while lung cancer treatment Alimta
jumped 35 percent to &36;142 million,
amid concerns that such drugs pose heart risks and cause
psychiatric problems, such as drug for treatment of erectile dysfunction.
the New York Stock Exchange. They are up 12 percent in 2007,
outpacing a 2 percent rise for the American Stock Exchange
Pharmaceutical index. (.DRG)
You can skip to the end and leave a response. Pinging is currently not allowed.